Sarepta Therapeutics (SRPT, $147.64) was one of top quarterly gainers, jumping +1 to $147.64 per share. A.I.dvisor analyzed 873 stocks in the Biotechnology Industry over the last three months, and discovered that of them (6) charted an Uptrend while of them (3) trended down. A.I.dvisor found 307 similar cases when SRPT's price went up within three months. In out of those 307 cases, SRPT's price went down during the following month. Based on these historical data, A.I. thinks the odds of an Uptrend reversal for SRPT are